Related Experiment Video

Updated: Nov 10, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.0K

Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer

Seung Wan Son1, Mun Gyu Song1, Ba Da Yun1

  • 1Department of Biomedical Science, Hallym University, Chunchon 24252, Korea.

Biomedicines
|April 3, 2021
PubMed

Insights

Noncoding RNAs (ncRNAs) are crucial in regulating cellular events that drive therapeutic resistance in cancer. Targeting ncRNAs shows promise for improving pancreatic cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Therapeutic resistance is a major challenge in cancer treatment, driven by complex cellular mechanisms.
  • Signaling pathways regulate key events like epithelial-to-mesenchymal transition (EMT), stemness, and apoptosis, contributing to resistance.
  • Noncoding RNAs (ncRNAs) are vital gene regulators whose altered expression is implicated in cancer pathology.

Purpose of the Study:

  • To review the current understanding of human ncRNAs' role in therapeutic resistance.
  • To explore the potential of ncRNAs as therapeutic targets, particularly in pancreatic cancer.

Main Methods:

  • Literature review of recent evidence on ncRNAs and therapeutic resistance.
  • Focus on molecular mechanisms and gene regulatory networks.
  • Analysis of ncRNA dysregulation in cancer contexts.

Main Results:

  • ncRNAs are significantly altered in cancer and contribute to resistance mechanisms.
  • Dysregulated ncRNAs participate in complex gene regulatory networks.
  • Evidence suggests ncRNAs are involved in EMT, stemness, cell survival, and autophagy.

Conclusions:

  • Understanding ncRNA roles is essential for overcoming therapeutic resistance.
  • ncRNAs represent a promising avenue for novel therapeutic strategies in pancreatic cancer.
  • Targeting ncRNAs could enhance the efficacy of existing cancer therapies.
Keywords:
circular RNAlong noncoding RNAmicroRNAnoncoding RNApancreatic cancertherapeutic resistance

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

831

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.3K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.9K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.0K